← Leaderboards
Thomas P Quinn
Neorx Corporation
$3,207,797
Attributed
$4,556,483
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $870.6K · FY2007–19$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$4,556,483 · 7
By mechanism
U54$1,583,216 · 1
R01$1,322,451 · 1
R21$934,104 · 2
R42$500,726 · 1
R41$215,986 · 2
Top collaborators
- Bernard Mark Evers5 shared
- Peixuan Guo5 shared
- Marc Robillard3 shared
- Liaohai Chen2 shared
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadRadiotracerRadioisotopesDoseTumorIn VivoInnovationRadiolabeledNanoparticleMalignant NeoplasmsBaseMouse ModelUptakeIn VitroBiodistributionCellsPropertyLabelCancer TherapyResistancePeptidesAffinityDrug KineticsBinding (Molecular Function)
Grant awards (19)
Melanocortin-1 Receptor Targeted Ultrasmall Silica nanoparticles for Alpha- and$311,857
U54 · FY2019 · CA · contact PI
Melanocortin-1 Receptor Targeted Ultrasmall Silica nanoparticles for Alpha- and$319,824
U54 · FY2018 · CA · contact PI
Melanocortin-1 Receptor Targeted Ultrasmall Silica nanoparticles for Alpha- and$322,300
U54 · FY2017 · CA · contact PI
Cancer specific and organ-avoiding RNA architectures for quantitative imaging$316,417
R01 · FY2017 · EB
Cancer specific and organ-avoiding RNA architectures for quantitative imaging$320,423
R01 · FY2016 · EB
Melanocortin-1 Receptor Targeted Ultrasmall Silica nanoparticles for Alpha- and$317,263
U54 · FY2016 · CA · contact PI
Melanocortin-1 Receptor Targeted Ultrasmall Silica nanoparticles for Alpha- and$311,972
U54 · FY2015 · CA · contact PI
Cancer specific and organ-avoiding RNA architectures for quantitative imaging$292,719
R01 · FY2015 · EB
In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy$214,667
R21 · FY2015 · CA · contact PI
Cancer specific and organ-avoiding RNA architectures for quantitative imaging$51,270
R01 · FY2015 · EB
Cancer specific and organ-avoiding RNA architectures for quantitative imaging$341,622
R01 · FY2014 · EB
In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy$190,493
R21 · FY2014 · CA · contact PI
In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy$174,634
R21 · FY2013 · CA · contact PI
Peptide-targeted alpha-particle emitting phage for ovarian cancer therapy.$150,578
R21 · FY2013 · CA · contact PI
Peptide-targeted alpha-particle emitting phage for ovarian cancer therapy.$203,732
R21 · FY2012 · CA · contact PI
Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells$115,953
R41 · FY2007 · CA · contact PI
Melanoma Therapy via peptide targeted alpha-radiation$252,667
R42 · FY2004 · CA
Melanoma Therapy via peptide targeted alpha-radiation$248,059
R42 · FY2002 · CA
MELANOMA RADIOTHERAPY- PEPTIDE TARGETED ALPHA-RADIATION$100,033
R41 · FY2000 · CA